- By Boris Ladwig | Posted on February 7, 2019
Apellis Pharmaceuticals said that its APL-2 drug has received approval from the Food and Drug Administration to be designated an “orphan drug” for two blood-related autoimmune diseases. The designation qualifies the Crestwood, Ky.-based pharmaceutical company for development incentives, including tax credits. Apellis said the...
Monday Business Briefing: Lexington pizzeria coming; council to vote on Topgolf hearing; CafePress deal done; Yelp Art in Action; and moreBy Staff | Posted on November 11, 2018
Welcome to the Nov. 12 Monday Business Briefing, your weekly business intelligence digest from Insider Louisville.
- By Boris Ladwig | Posted on November 9, 2018
Turning Point Brands fell 3.4 percent Friday morning after The Washington Post reported that the FDA plans to “impose severe restrictions” on sales of e-cigarette products.
- By Boris Ladwig | Posted on September 12, 2018
Shares of the Louisville-based tobacco company Turning Point Brands fell more than 10 percent Thursday morning after the FDA chief issued an e-cigarette warning, calling youth use of the product an “epidemic” and a “clear and present danger.”